---
title: post-remission therapy of treatment of acute lymphoblastic leukemia (ALL)
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[treatment of acute lymphoblastic leukemia (ALL)]]

# post-remission therapy of treatment of acute lymphoblastic leukemia (ALL)
Â (choice depends on risk of recurrence)

1. Average risk ðŸ’š
- consolidation/intensification chemo (~7 mo)
- â†’ maintenance (~2â€“3 y)

2. High risk ðŸ”´
- high-dose chemo w/ allo-HSCT considered for Pts in CR1.
- High-risk disease:
	- Ph âŠ•
	- Ph-like
		- (based on gene expression)
	- MLL translocation
		- t(4;11)
	- complex karyotype
	- hypodiploid
		- (<44 chromosomes)
	- early T-cell phenotype
		- (ETP; lacks CD1a, CD8, CD5weak, myeloid markers)
	- minimal residual disease (MRD)
		- morphologic remission
		- but flow cytometry or molec. markers of tumor still detectable.

